These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 34285106)

  • 1. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
    Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
    Ivasko SM; Anders K; Grunewald L; Launspach M; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Lode HN; Andersch L; Schulte JH; Eggert A; Hundsdoerfer P; Künkele A; Zirngibl F
    Front Immunol; 2022; 13():1023206. PubMed ID: 36700232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
    Ruf P; Schäfer B; Eissler N; Mocikat R; Hess J; Plöscher M; Wosch S; Suckstorff I; Zehetmeier C; Lindhofer H
    J Transl Med; 2012 Nov; 10():219. PubMed ID: 23134699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery.
    Deppisch N; Ruf P; Eissler N; Neff F; Buhmann R; Lindhofer H; Mocikat R
    Mol Cancer Ther; 2015 Aug; 14(8):1877-83. PubMed ID: 26063765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3).
    Arendt AM; Heubach F; Maier CP; Giardino S; Jung G; Kowalewski E; Rabsteyn A; Amorelli G; Seitz C; Schlegel P; Handgretinger R; Lang P
    Cancer Immunol Immunother; 2023 Nov; 72(11):3813-3824. PubMed ID: 37742286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
    Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
    Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
    Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
    Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
    Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
    Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Cheng M; Ahmed M; Xu H; Cheung NK
    Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
    Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
    Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
    Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
    Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.